CovidAntibodyCocktailDrug
Covid antibody cocktail, used for treating Donald Trump, launched in India
New Delhi/IBNS: Pharmaceutical major Roche India on Monday announced that it has launched the first batch of antibody cocktail against COVID-19 in the Asian country.
The antibody cocktail, combining Casirivimab and Imdevimab, has been priced at ₹ 59,750 per dose.
Roche's antibody cocktail was given to former US President Donald Trump when he tested positive COVID-19 last year.
In a statement, the company said: "Each of the 1,200 mg dose of the drug contains 600 mg of Casirivimab and 600 mg of Imdevimab. The price of each dose will be ₹ 59,750. The maximum retail price for the multi-dose pack will be ₹ 1,19,500. Notably, each pack can treat two patients."
The drug will be marketed in India by Cipla and the second batch will be made available by mid-June.
"The first batch of the antibody cocktail (Casirivimab and Imdevimab) is now available in India while a second batch will be made available by mid-June. In total they can potentially benefit two lakh patients as each of the one lakh packs that will be available in India offers treatment for two patients," according to a joint statement issued by Cipla and Roche.
The drug will be made available through leading hospitals and COVID treatment centre in India.
The Central Drugs Standards Control Organisation (CDSCO) had recently provided an Emergency Use Authorisation (EUA) for the antibody cocktail's use in India.
Support Our Journalism
We cannot do without you.. your contribution supports unbiased journalism
IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.
Support objective journalism for a small contribution.
